Out of the 21 BC presenting 2 CEP17 s/n, 1 (5%) was HER2 amplified (mean value ≥1.5) by MLPA, 2 (9%) showed a gain (mean value ≥1.3 but <1.5), the other 18 resulted HER2 non amplified (mean value <1.3). This evidence concerns the gene ERBB2 and breast cancer.